# Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients

> **NCT03905109** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Abivax S.A.**

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** ABX464
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03905109
- **Lead sponsor:** Abivax S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-09-19
- **Primary completion:** 2022-09-19
- **Final completion:** 2022-09-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study design revised and to be found under new NCT06456593 ABX464-202
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03905109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03905109, "Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03905109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*